According to Baxalta’s press statement, M923 met the primary endpoint, which was to evaluate the pharmacokinetics of M923 compared to both US and EU sourced Humira (adalimumab) reference products.

The trial was a randomized, double-blind, three-arm, parallel group, single-dose study, which enrolled 324 healthy volunteers. In addition to ‘showing bioequivalence in pharmacokinetics’, the study also evaluated safety, tolerability and immunogenicity following single doses of M923 given by injection.

Dr Jim Roach, Senior Vice President of Development and Chief Medical Officer of Momenta Pharmaceuticals said of the results that they ‘further validate our ability to develop high quality biosimilar candidates using our complex systems analysis platform’. He expects the results seen to date and ‘the data we generate from our ongoing pivotal trial in patients with chronic plaque psoriasis will continue to support the demonstration of biosimilarity of M923 to branded Humira’.

Baxalta and Momenta also announced the start of a phase III trial with M923 in patients with chronic plaque psoriasis in October 2015 [1]. The companies aim to have their first regulatory submission in 2017 and to launch the biosimilar as early as 2018.

Related article
Biosimilars of adalimumab 

Reference
1.  GaBI Online - Generics and Biosimilars Initiative. Baxalta and Momenta start phase III trial for adalimumab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Feb 12]. Available from: www.gabionline.net/Biosimilars/News/Baxalta-and-Momenta-start-phase-III-trial-for-adalimumab-biosimilar 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.